Abstract: The disclosure provides a use of C3aR in preparing drugs for preventing or treating polycystic kidney disease, belonging to the technical field of medicines. The disclosure discovers that C3aR inhibitor can down-regulate or reduce the C3aR level by inhibiting proliferation of cyst epithelial cells, blocking chemotaxis of C3a-C3aR on macrophages, inhibiting the interaction between C3a and C3aR, and expressing the p-ERK, p-P65 proteins, and then prevent cyst growth, improve the inflammatory state, thus treating polycystic kidney disease. The C3aR inhibitor can be used for the development of novel lead compounds for preventing or treating autosomal dominant polycystic kidney disease, and also can be used for preparing drugs for preventing or treating polycystic kidney disease.

Abstract: The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPAR? agonist, through activating PPAR-RXR heterodimers that interacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.

Abstract: This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

Abstract: The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPAR? agonist, through activating PPAR-RXR heterodimers that intereacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.

Abstract: This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.